Marinus Pharmaceuticals Completes Enrollment in Phase 3 Trial For Ganaxolone Anti-Seizure Treatment

Print 18 December 2015
The Stock Informant

Marinus Pharmaceuticals (NASDAQ:MRNS), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The company anticipates announcing top-line results from the study in mid-2016. In the Phase 2 study that was conducted in patients experiencing drug-resistant seizures for more than 25 years, ganaxolone met the primary endpoint and was safe and well-tolerated. Marinus shares closed at $6.12 on Tuesday with a 52-week spread of $4.52 – $20.72.

The stock increased 0.33% or $0.02 during the last trading session, hitting $6.14. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 24.10% since May 14, 2015 and is downtrending. It has underperformed by 21.84% the S&P500.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is based in Radnor, Pennsylvania.

Source

Return